Literature DB >> 17401095

Human antibody against C domain of tenascin-C visualizes murine atherosclerotic plaques ex vivo.

Tobias von Lukowicz1, Michela Silacci, Matthias T Wyss, Eveline Trachsel, Christine Lohmann, Alfred Buck, Thomas F Lüscher, Dario Neri, Christian M Matter.   

Abstract

UNLABELLED: Targeting proteins that are overexpressed in atherosclerotic plaques may open novel diagnostic applications. The C domain of tenascin-C is absent from normal adult tissues but can be inserted during tumor progression or tissue repair into the molecule by alternative splicing. We tested the ability of the human antibody G11, specific to this antigen, to reveal murine atherosclerotic plaques ex vivo. The antibody directed against the extra domain B of fibronectin (L19) was used as a reference.
METHODS: We intravenously injected (125)I-labeled G11 or L19 antibodies into apolipoprotein E-deficient (ApoE(-/-)) mice and harvested the aortae 4 or 24 h later. En face analyses of distal aortae and longitudinal sections of the aortic arch were performed to compare antibody uptake using autoradiography with plaque staining using oil red O. Plaque macrophages were detected by immunohistochemistry (anti-CD68 staining). Biodistribution of injected antibodies was investigated in aortae and blood at 4 and 24 h.
RESULTS: En face analyses revealed a significant correlation between radiolabeled G11 and fat-stained areas, increasing from 4 to 24 h, with a correlation coefficient of 0.92 (P < 0.0001) and an average signal-to-noise ratio of 104:1 at 24 h. Plaque imaging using L19 showed similar results (r = 0.86; P < 0.0001; signal-to-noise ratio, 72:1 at 24 h). Uptake of radiolabeled antibodies in histologic sections colocalized with fat staining and activated macrophages in aortic plaques. Biodistribution analyses confirmed specific accumulation in aortic plaques as well as rapid blood pool clearance of the antibodies 24 h after injection. Immunofluorescence analyses revealed increased expression of tenascin and fibronectin isoforms in macrophage-rich plaques.
CONCLUSION: The antibody G11, specific to the C domain of tenascin-C, visualizes murine atherosclerotic plaques ex vivo. In conjunction with the increased expression of the C domain of tenascin-C in macrophage-rich plaques, the colocalization of G11 uptake with activated macrophages, and the favorable target-to-blood ratio at 24 h, this antibody may be useful for molecular imaging of advanced atherosclerotic plaques in the intact organism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401095     DOI: 10.2967/jnumed.106.036046

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  Differential vascular expression and regulation of oncofetal tenascin-C and fibronectin variants in renal cell carcinoma (RCC): implications for an individualized angiogenesis-related targeted drug delivery.

Authors:  Kerstin Galler; Kerstin Junker; Marcus Franz; Julia Hentschel; Petra Richter; Mieczyslaw Gajda; Angela Göhlert; Ferdinand von Eggeling; Regine Heller; Raffaella Giavazzi; Dario Neri; Hartwig Kosmehl; Heiko Wunderlich; Alexander Berndt
Journal:  Histochem Cell Biol       Date:  2011-11-11       Impact factor: 4.304

Review 2.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

Review 3.  PET and SPECT in cardiovascular molecular imaging.

Authors:  Lawrence W Dobrucki; Albert J Sinusas
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 4.  Tenascin-C in cardiovascular remodeling: potential impact for diagnosis, prognosis estimation and targeted therapy.

Authors:  Marcus Franz; Christian Jung; Alexander Lauten; Hans R Figulla; Alexander Berndt
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

5.  Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies.

Authors:  Marcus Franz; Bernhard R Brehm; Petra Richter; Katja Gruen; Dario Neri; Hartwig Kosmehl; Khosro Hekmat; Andre Renner; Jan Gummert; Hans R Figulla; Alexander Berndt
Journal:  J Mol Histol       Date:  2010-03-16       Impact factor: 2.611

6.  Polymorphic variants in tenascin-C (TNC) are associated with atherosclerosis and coronary artery disease.

Authors:  Mollie A Minear; David R Crosslin; Beth S Sutton; Jessica J Connelly; Sarah C Nelson; Shera Gadson-Watson; Tianyuan Wang; David Seo; Jeffrey M Vance; Michael H Sketch; Carol Haynes; Pascal J Goldschmidt-Clermont; Svati H Shah; William E Kraus; Elizabeth R Hauser; Simon G Gregory
Journal:  Hum Genet       Date:  2011-02-05       Impact factor: 4.132

Review 7.  Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview.

Authors:  L M Riou; A Broisat; J Dimastromatteo; G Pons; D Fagret; C Ghezzi
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

8.  The role of tenascin-C in tissue injury and tumorigenesis.

Authors:  Kim S Midwood; Gertraud Orend
Journal:  J Cell Commun Signal       Date:  2009-10-17       Impact factor: 5.782

Review 9.  Imaging of the unstable plaque: how far have we got?

Authors:  Christian M Matter; Matthias Stuber; Matthias Nahrendorf
Journal:  Eur Heart J       Date:  2009-10-15       Impact factor: 29.983

10.  Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.

Authors:  J K J Ahlskog; C Schliemann; J Mårlind; U Qureshi; A Ammar; R B Pedley; D Neri
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.